Mankind Pharma Ltd

  • BSE Code : 543904
  • NSE Symbol : MANKIND
  • ISIN : INE634S01028
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 1,998.50 -2.80(-0.14%)

Open Price ()

2,000.00

Prev. Close ()

2,001.30

Volume (No’s)

593,771

Market Cap ()

82,503.74

Low Price ()

1,928.00

High Price ()

2,005.00

 

Board Meetings

Start Date End Date Purpose
09-Jan-2026 03-Feb-2026 Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 inter alia to consider and approve approval of unaudited standalone and consolidated financial results of the company for the quarter and nine months ended on December 31 2025. Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. (As Per NSE Announcement Dated On : 03.02.2026)
27-Oct-2025 06-Nov-2025 Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30 2025. Un-audited Financial Results for the Quarter and Half Year ended 30.09.2025 Financial Results for the quarter and half year ended 30th September 2025 (As Per BSE Announcement Dated on: 06/11/2025)
03-Aug-2025 03-Aug-2025 We wish to inform you that the Company has today, i.e. August 3, 2025, submitted application for reclassification of Ayushi and Poonam Estates LLP from the 'Promoter and Promoter Group' Category to 'Public' Category.
14-Jul-2025 31-Jul-2025 Quarterly Results & Interim Dividend Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 & 50 of the Listing Regulations, we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, July 31, 2025, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2025; and declaration of interim dividend, if any, for the financial year 2025-26. (As Per BSE Announcement dated on 14.07.2025) Outcome of Board Meeting held on July 31, 2025. (As per BSE Announcement Dated on 31/07/2025)
08-May-2025 21-May-2025 Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2025 inter alia to consider and approve Pursuant to Regulation 29 and 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday May 21 2025 inter-alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31 2025. Further in continuation of our earlier letter dated March 26 2025 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till May 23 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 21/05/2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew